Sampling circulating tumor cells for clinical benefits: how frequent?

Journal of Hematology & Oncology

Evelyn SC Koay⁵  Steven Tucker¹  Mo-Huang Li³  Saabry Osmany⁴  Delly Fareda¹  Doreen Tan¹  Hui Wen Chua²  Karen ML Tan²  Sai Mun Leong² 

[1] Tucker Medical, Novena Specialist Center, 8 Sinaran Drive #04-03, Singapore 307470, Singapore;Department of Laboratory Medicine, National University Hospital, Level 3 NUH Main Building, 5 Lower Kent Ridge Road, Singapore 119074, Singapore;CellSievo Private Limited Singapore, Block 289A, Bukit Batok St. 25, #15-218, Singapore 650289, Singapore;Radlink PET and Cardiac Imaging Center, 290 Orchard Road, #08-06 Paragon Medical, Singapore 238859, Singapore;Department of Pathology, National University of Singapore, Level 3 NUH Main Building, 5 Lower Kent Ridge Road, Singapore 119074, Singapore

关键词: Monitoring frequency;    Sampling interval;    Cancer;    Therapeutic monitoring;    Circulating tumor cells;   

Others  :  1219923
DOI  :  10.1186/s13045-015-0174-9

 received in 2015-04-23, accepted in 2015-06-15,  发布年份 2015

【 摘 要 】

Circulating tumor cells (CTCs) are cells shed from tumors or metastatic sites and are a potential biomarker for cancer diagnosis, management, and prognostication. The majority of current studies use single or infrequent CTC sampling points. This strategy assumes that changes in CTC number, as well as phenotypic and molecular characteristics, are gradual with time. In reality, little is known today about the actual kinetics of CTC dissemination and phenotypic and molecular changes in the blood of cancer patients. Herein, we show, using clinical case studies and hypothetical simulation models, how sub-optimal CTC sampling may result in misleading observations with clinical consequences, by missing out on significant CTC spikes that occur in between sampling times. Initial studies using highly frequent CTC sampling are necessary to understand the dynamics of CTC dissemination and phenotypic and molecular changes in the blood of cancer patients. Such an improved understanding will enable an optimal, study-specific sampling frequency to be assigned to individual research studies and clinical trials and better inform practical clinical decisions on cancer management strategies for patient benefits.

【 授权许可】

   
2015 Leong et al.

【 图 表 】

Fig. 2.

Fig. 1.

Fig. 3.

【 参考文献 】

• [1]Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aus Med J. 1869; 14:146-9.
• [2]Lang JM, Casavant BP, Beebe DJ. Circulating tumor cells: getting more from less. SciTransl Med. 2012; 4:141ps13.
• [3]King JD, Casavant BP, Lang JM. Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. Lab Chip. 2014; 14:24-31.
• [4]Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al.. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351:781-91.
• [5]Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L et al.. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012; 13:688-95.
• [6]Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005; 65:713-8.
• [7]Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al.. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20:1223-9.
• [8]Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T et al.. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011; 29:1651-60.
• [9]Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D et al.. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 2011; 122:567-72.
• [10]Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K et al.. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem. 2014; 60:214-21.
• [11]Igawa S, Gohda K, Fukui T, Ryuge S, Otani S, Masago A et al.. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett. 2014; 7:1469-73.
• [12]Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC et al.. Circulating tumor cells at each follow-up time-point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12:4218-24.
• [13]Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E et al.. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol. 2008; 19:891-7.
• [14]Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D et al.. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15:406-14.
• [15]de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al.. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14:6302-9.
• [16]Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al.. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26:3213-21.
• [17]Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al.. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25:5287-312.
• [18]Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M et al.. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008; 26:1208-15.
• [19]Marsland T, Schuur ER. Circulating tumor cell data: integration with imaging and serum tumor markers for metastatic breast cancer patient management. Case Rep Oncol. 2014; 7:175-81.
• [20]Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al.. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359:355-77.
• [21]Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT et al.. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339:580-4.
• [22]Pachmann K, Camara O, Kohlhase A, Rabenstein C, Kroll T, Runnebaum IB et al.. Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. J Cancer Res Clin Oncol. 2011; 137:821-8.
• [23]Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012; 12:323-34.
• [24]Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S et al.. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008; 14:7004-10.
• [25]Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M et al.. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant Gepar Quattro trial. Clin Cancer Res. 2010; 16:2634-45.
• [26]Lim LS, Hu M, Huang MC, Cheong WC, Gan AT, Looi XL et al.. Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip. 2012; 12:4388-96.
• [27]Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis CH, Apostolaki S et al.. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002; 20:3404-12.
• [28]Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, Scanni A et al.. Detection of micrometastatic cells in breast cancer by RT-PCR for the mammaglobin gene. Cancer Detect Prev. 2002; 26:60-3.
• [29]Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K et al.. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000; 156:57-63.
• [30]Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003; 162:149-55.
• [31]Becker FF, Wang XB, Huang Y, Pethig R, Vykoukal J, Gascoyne PR. Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A. 1995; 92:860-4.
• [32]Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al.. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450:1235-9.
• [33]Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA et al.. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010; 107:18392-7.
• [34]Alix-Panabières C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res. 2012; 195:69-76.
• [35]Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S et al.. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009; 119:3172-81.
• [36]Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol. 2009; 132:237-45.
• [37]Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol. 2014; 25:1506-16.
• [38]Plaks V, Koopman CD, Werb Z. Circulating tumor cells. Science. 2013; 341:1186-8.
• [39]Pantel K, Denève E, Nocca D, Coffy A, Vendrell JP, Maudelonde T et al.. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012; 58:936-40.
• [40]Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA et al.. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158:1110-22.
• [41]Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L et al.. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2:25ra23.
• [42]Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T et al.. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9: Article ID e101777
• [43]McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011; 364:340-50.
• [44]Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al.. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352:786-92.
• [45]Kuo CH, Lin SM, Lee KY, Chung FT, Hsieh MH, Fang YF et al.. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer. 2010; 11:51-6.
• [46]Guo R, Chen X, Wang T, Zhang Z, Sun J, Shu Y. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer. 2011; 11:20-90. BioMed Central Full Text
• [47]Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011; 305:2335-42.
• [48]Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol. 2008; 19:400-2.
• [49]Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2013; 13:240. BioMed Central Full Text